Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P, Pantani L, Patriarca F, Petrucci MT, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, Barbato S, Tosi P, Narni F, Montefusco V, Testoni N, Spadano A, Terragna C, Pescosta N, Marzocchi G, Cellini C, Galieni P, Ronconi S, Gobbi M, Catalano L, Lazzaro A, De Sabbata G, Cangialosi C, Ciambelli F, Musto P, Elice F, Cavo M; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto Italian Myeloma Network). Tacchetti P, et al. Among authors: montefusco v. Lancet Haematol. 2020 Dec;7(12):e861-e873. doi: 10.1016/S2352-3026(20)30323-9. Lancet Haematol. 2020. PMID: 33242443 Clinical Trial.
Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.
Martinelli G, Montefusco V, Amabile M, Lemoli RM, Terragna C, Testoni N, Ottaviani E, Rosti G, de Vivo A, Rizzi S, Russo D, Bregoli M, Tura S. Martinelli G, et al. Among authors: montefusco v. Leuk Lymphoma. 2000 Sep;39(1-2):113-20. doi: 10.3109/10428190009053544. Leuk Lymphoma. 2000. PMID: 10975389
Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.
Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli R, Bandini G, Testoni N, Amabile M, Ottaviani E, Buonamici S, Soverini S, Montefusco V, de Vivo A, Bonifazi F, Tura S, Cavo M. Martinelli G, et al. Among authors: montefusco v. Haematologica. 2000 Sep;85(9):930-4. Haematologica. 2000. PMID: 10980631
Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.
Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, Amabile M, Terragna C, Ruggeri D, Piccaluga PP, Isidori A, Malagola M, Baccarani M, Tura S, Martinelli G. Buonamici S, et al. Among authors: montefusco v. Blood. 2002 Jan 15;99(2):443-9. doi: 10.1182/blood.v99.2.443. Blood. 2002. PMID: 11781223 Free article.
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.
Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Corradini P, et al. Among authors: montefusco v. Blood. 2003 Sep 1;102(5):1927-9. doi: 10.1182/blood-2003-01-0189. Epub 2003 May 8. Blood. 2003. PMID: 12738666 Free article. Clinical Trial.
100 results